Jan. 21, 2013
/CNW Telbec/ - Capital Pro-Égaux Inc. (the "Company") (NEX: CPE.H) announces that its US counsels have been advised that a judge of the Eastern District of
Division, has granted all of Nobel Biocare's motions for summary judgment of non-infringement. Such motions were filed by Nobel in response to the Company's proceedings for patent infringement undertaken against Nobel in the summer of 2012 as described in the Company's Management Discussion and Analysis for the six-month period ended August 31, 2012. The details of the judgment have not yet been received but, based on our attorneys' preliminary input, it is likely that the Company will be appealing this decision in due course.
Caution regarding forward-looking statements
This news release contains certain forward-looking statements regarding the Company's expectation of certain future legal actions in connection with the proceedings against Nobel. Such expectations are based on certain assumptions based on currently available information. Depending on new information and further analysis, the Company may change its plans. The Company disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, other than as required by securities laws.
About Pro-Égaux Inc.
Pro-Égaux through its wholly owned subsidiary, Technique d'usinage Sinlab Inc., is a company based in
, specializing mainly in the conception and design of titanium products to be used in the dental prosthesis restoration industry.
Neither NEX, the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of NEX and the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE CAPITAL PRO-EGAUX INC.